Finally, 111 female BRCA1/2 mutation carriers who had not undergone risk-reducing surgery (i.e., salpingo oophorectomy) participated in a screening program involving both annual breast cancer screening and OC screening involving both CA125 testing and TVS [26]. This evidence concerns the gene MUC16 and breast carcinoma.